InvestorsHub Logo
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 717

Thursday, 02/09/2023 9:11:31 AM

Thursday, February 09, 2023 9:11:31 AM

Post# of 751
ABBV reports 4Q22 results—issues 2023 guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results.htm

ABBV’s 2023 non-GAAP EPS guidance is $10.70-11.10, a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News